China approves two self-developed COVID-19 drugs

China approves two self-developed COVID-19 drugs

China approved two domestically developed drugs for COVID-19 patients with mild and moderate symptoms, the country's National Medical Products Administration said on Sunday.


The small-molecule oral drugs, used for treating adult patients with mild to moderate COVID-19 infections, have been declared by Hainan Simcere Pharmaceutical Co., Limited and Shanghai Wangshi Biological Medicine Technology Co., LTD., according to a statement on the administration's website.

There are more than 600 medications used for colds, fever and coughs to treat COVID-19 infection in the country's current medical insurance catalog, according to Huang Xinyu, an official at the National Healthcare Security Administration, at a press conference held on January 11.

International Conference on Infectious Diseases

visit: infectious.pencis.com